NANETS Phili

NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

September 17, 2022

7:30am – 4:00pm

Earn up to 6.75 AMA PRA Category 1 Credits,™ Continuing Nursing Education (CNEG), and MOC accreditation

Register Here


Location

Sheraton Philadelphia Downtown
201 N. 17th Street
Philadelphia, PA 19103

Providers

Jointly Provided by Penn Medicine, Fox Chase Cancer Center, and the North American Neuroendocrine Tumor Society

Course Directors

Jennifer R. Eads, MD; Penn Medicine and Namrata Vijayvergia, MD; Fox Chase Cancer Center, Temple University Health System

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time-consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

7:30-8:00 am
8:00-8:10 am
Registration and Breakfast
Welcome and Opening Remarks
    • Jennifer R. Eads, MD; Penn Medicine and Namrata Vijayvergia, MD; Fox Chase Cancer Center, Temple University Health System
8:10-8:30 am
Overview of Neuroendocrine Tumors
    • Overview of NETs and New Grading
      Jennifer R. Eads, MD, Associate Professor of Clinical Medicine, Penn Medicine
    • Diagnosing NETs
      Jordan Anaokar, MD, Associate Professor, Department of Diagnostic Imaging, Site Director, Radiology, Fox Chase Cancer Center, and Yulan Gong, MD, Assistant Professor, Department of Pathology, Fox Chase Cancer Center
8:30-9:40 am
Surgical Treatment of NETs
    • Localized GEPNETs
      Sanjay S. Reddy, MD, FACS, Associate Professor, Department of Surgical Oncology, Associate Program Director, Complex General Surgical Oncology Fellowship, Fox Chase Cancer Center and Co-Director, Marvin & Concetta Greenberg Pancreatic Cancer Institute
    • Localized Lung NETs
      Sunil Singhal, MD, Chief of the Division of Thoracic Surgery, Vice Chair of Translational Research, Department of Surgery, Penn Medicine
    • Debulking
      Jason A. Castellanos, MD, MS, Assistant Professor, Department of Surgical Oncology, Fox Chase Cancer Center
    • Endoscopic Procedures
      Galen Leung, MD, Assistant Professor of Clinical Medicine, Penn Medicine
9:40-10:45 am
Medical Management of NETs
    • GI NETs and PancNETs
      Namrata Vijayvergia, MD, Assistant Chief, Gastrointestinal Medical Oncology, Associate Professor, Department of Hematology/Oncology, Fox Chase Cancer Center
    • Lung NETs
      Aditi Singh, MD, Assistant Professor of Clinical Medicine, Penn Medicine
10:45-11:00 am
Break
11:00 – 11:35 am
Peptide Receptor Radionuclide Therapy (PRRT)
    • PRRT As It Is Now
      Jian Q. (Michael) Yu, MD, FACNM, FRCPC, Chief, Nuclear Medicine and PET, Professor, Department of Diagnostic Imaging, Fox Chase Cancer Center
    • Innovative PRRT Therapies: Dosimetry, New Isotopes, and Ligands
      David Mankoff, MD, PhD, Vice Chair for Research, Radiology Matthew J. Wilson Professor of Research Radiology, Penn Medicine
11:35 – 12:10 pm
Locoregional Therapies
    • Interventional Radiology (IR)
      Michael Soulen, MD, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine
    • Radiation
      Joshua Meyer, MD, Vice Chair, Translational Research, Professor, Department of Radiation Oncology, Fox Chase Cancer Center 
12:10-1:10 pm
Lunch
1:10 – 2:00 pm
Paraganglioma/Pheochromocytoma
    • Medical Management
      Vivek Narayan, MD, MS, Assistant Professor of Medicine; Hospital of the University of Pennsylvania
    • Surgical Management of Abdominal Tumors
      Rosalia Viterbo, MD, FACS, Associate Professor, Department of Surgical Oncology, Fox Chase Cancer Center
    • Surgical Management of Head and Neck Tumors
      Christopher Rassekh, MD, Professor of Clinical Otorhinolaryngology: Head and Neck Surgery, Penn Medicine
    • Radionuclides Therapy
      Sophia Rose O'Brien, MD, Assistant Professor of Clinical Radiology, Penn Medicine
2:00-3:00 pm
Additional Important Topics in NETs
    • Management of Functional Tumors and Hormone Symptoms
      Christian A. Koch, MD, PhD, FACP, MACE, Director, Division of Endocrinology, Professor, Department of Medicine, Endocrinologist, Fox Chase Cancer Center
    • Carcinoid Heart Disease
      Joseph Carver, MD, Chief of Staff, Abramson Cancer Center, Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania
    • Genetics
      Hannah R. Campbell, ScM, LCGC, Genetic Counselor, Fox Chase Cancer Center
3:00-4:00 pm
Tumor Board and Concluding Remarks
    • Panel of Presenters

 

 Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

 

In-person registration is available onsite the day of the program and will be accommodated on a space-available basis. Online registration is open until Thursday, September 15, 2022, 12 pm EST

Registration Fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Register Here 

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before August 26, 2022. On or after August 27, 2022, no refund will be made.

Penn Medicine, Temple University Health System, and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.